Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Shukui Qin et al.|Journal of Clinical Oncology|2013Cited by 775
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Alexey V. Sorokin et al.|Journal of Clinical Oncology|2020Cited by 391
Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra Sohal, Daniel A. Laheru, Erin B. Kennedy et al.|Journal of Clinical Oncology|2020Cited by 287
A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic CarcinomaMark S. Talamonti, Cornelius J. McGinn, William Small et al.|Annals of Surgical Oncology|2006Cited by 237